Scientific advances and regulatory incentives are driving the use of genetics in drug development, though the industry’s ability to perform wide-scale testing has outpaced its understanding of the results, the misinterpretation of which can have “disastrous”...
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
Saga Diagnostics AB secures venture-backed financing to advance its precision oncology genomics testing technology, which is being used to monitor patient responses in clinical trials, among other applications.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.
Social, cultural, and financial barriers pose a challenge in enrollment for oncology clinical trials, but USC investigator believes mitigating barriers to diversify research may provide comprehensive data.
Kazia therapeutics is collaborating with the Alliance for Clinical Trials in Oncology Foundation to launch a Phase II study to investigate its brain cancer therapies targeted at tumors’ genetic profile.